The PIONEER Big Data Platform offers a central and federated state-of-the-art Big Data analytic platform for prostate cancer. The platforms anonymous data is harmonised to the European Common Data Model, OMOP-CDM, following all legal and ethical requirements. The PIONEER Big Data platform brings together diverse datasets, contributed by our Partners and Associated Members, including the […]Read more
In the SUISSE MPC 2 study (Stress Urinary Incontinence Study to assess Safety and Efficacy of Muvon’s Muscle Precursor Cell Therapy), researchers at the University of Zurich are currently investigating a novel treatment option. This is a so-called “Phase II study”, which is designed to assess the efficacy and safety of the new treatment option.
MUVON THERAPEUTICS IS URGENTLY LOOKING FOR PATIENTS WHO ARE WILLING TO TAKE PART IN THIS TRIAL IN SWITZERLAND.
EPF joined the stakeholders’ consensus response to the proposed European Health Data Space (EHDS) On 20 October, EPF joined a group of 29 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space (EHDS). The stakeholders, including medical professional and research organisations, patient representatives, industry associations, and data collaborations, strongly support the aims […]Read more
We are pleased to present our compact Gastein Outcomes featuring an insight into discussions and key takeaways from our European Health Forum Gastein (EHFG) 2022 hybrid conference, accompanied by the witty illustrations of Floris Oudshoorn. Enjoy!Read more
On 17 and 18 October, the Health Outcomes Observatory (H2O) project held its General Assembly meeting in Basel, Switzerland. This was the first in-person general assembly for H2O, which began in October 2020. Our EPF colleagues Lyudmil, Valentina , and Estefania attended the meeting to represent our work on bringing patient engagement to the core of the project. The event was kicked-off […]Read more
EUnetHTA recently started an assessment on a medical device product for the treatment of men over 18 years of age with bothersome urinary symptoms associated with recurrent anterior urethral stricture. EUnetHTA 21 highly values patient involvement. What are we looking for? Patient organisation input We are seeking patient organisation input via an online questionnaire. This questionnaire aims […]Read more
On 21-23 September, the PROPHET project held its inaugural meeting in in Rome at the Università Cattolica del Sacro Cuore, the project coordinator. PROPHET is a Horizon Europe project, composed of 18 European partner organisations. The project aims to create a personalised prevention roadmap for the future of healthcare in Europe. The roadmap will be co-created together with […]Read more
Videos Peer-to-Peer Clinical Conversations Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR – Beyond the Abstract Patient perception of meaningful reductions in bothersome symptoms of overactive bladder (OAB) is lacking. VIEW The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder – Michael […]Read more
Let’s end bowel cancer and bowel disease. Newsletter | October 2022 Welcome to our new newsletter We are delighted to launch our new look newsletter. We have highlighted a few fundraising and medical research stories below. Please click on the links, where you’ll also find plenty more about the work of the charity, including new blogs from […]Read more
EAU Edu Platform on functional urology In this newsletter, we present to you the latest developments in functional urology. You can watch a video interview with Dr. Alexander Tamalunas (DE) about how Permixon™ inhibits adrenergic and non-adrenergic human prostate smooth muscle contraction. Our editorial board have selected some articles on male LUTS for you to read, and you can listen […]Read more
Muvon Therapeutics AG, an innovative clinical-stage biotechnology company, today announced that the first patient with Stress Urinary Incontinence has been enrolled as part of the planned Phase II clinical trial (SUISSE MPC 2-Study) using its novel proprietary cell therapy platform.Read more
On Saturday 26th November 2022, Novuqare Pelvic Health BV is organizing a “MAPLe® Day” in Mechelen, Belgium (language will be Dutch). During this day, MAPLe and the the knowledge of working with MAPLe is central. It is a day where, besides training, asking questions, exchanging experiences and meeting each other, we want to bring your […]Read more
Spread the word: Open Academy Schools 2023 Are any motivated and promising patient advocates known to your organisation? Make sure they apply to attend our Open Academy Schools taking place in Barcelona from 19 to 23 June 2023. To encourage applicants, we are providing flyers on why prospective advocates should apply for our School on Medicines […]Read more
Nominate your esteemed colleagues to be presented an award! Each year the EAU bestows a selection of prestigious awards to recognise and celebrate particular dedication and innovation in urological research and practice. The awards are a vital acknowledgement of members of our urological community who continue to push the limits of what is known to us today. Award winners […]Read more
Are You Asking The Right Questions About Incontinence Treatment? It’s Not Always About Finding The Best Absorbent Product. If you’re reading this, you are likely one of the hundreds of millions of people who have incontinence. We understand you may be frustrated, or resigned, or embarrassed with your condition. However, something has to be done, […]Read more